Organigram Global Inc. Common Shares (OGI)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses whose economics I can understand and whose price leaves a margin of safety. Organigram is a Canadian cannabis producer selling medical and recreational products under many brands. The industry is regulated, fragmented, and competitive; branding helps, but I see no durable competitive moat. The latest reported quarter, fiscal Q2 2026, showed revenue of $105.8 million and net income of $105.5 million, a 99.77% net margin. That is remarkable, and it makes the trailing P/E of 2.14 and P/B of 0.35, at the 2026-10-13 close of $0.92, look statistically cheap. FairStock also calculates a Graham Number of $5.77, an 84.07% margin of safety, and a PEG of 0.01. But the cash flow statement tells a different story: trailing free cash flow is -$29.7 million, a -14.8% FCF yield. ROCE is -0.60% even though ROE is 17.56%, and the Altman Z-Score of -0.06 and Piotroski F-Score of 4/9 suggest fragile financial health. Debt is modest at D/E 0.06, which helps. Growth has been rapid according to the provided figures, but FairStock assigns no Lynch category because there are only 0 years of filed annual results, needing 3. At 92 cents, the stock is priced for trouble. If the profit is real and free cash flow turns positive, it could be very cheap; if not, the low multiples are a value trap. I would demand a clearer record before trusting the accounting profits.

In plain English: Organigram Global makes and sells cannabis products in Canada. It has recently shown strong sales growth and a large quarterly profit, but it is still losing cash overall. At 92 cents, the shares look inexpensive compared with the company's reported earnings and accounting value, though the cash losses make the situation uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer